Minnesota Finalizes Expanded 340B Provider Reporting Requirements, Extends Submission Deadline to May 30

The Minnesota Department of Health issued updated reporting guidance last week for 340B providers.
Minnesota covered entities will have additional 340B reporting requirements this year, but an extended deadline to submit that data, according [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Tariffs on Pharmaceuticals Could Worsen Drug Shortages, Cause Disarray in 340B Prices, Advocates Say

President Trump said he will implement tariffs on pharmaceuticals in the “not too distant future.” Many of the details of these potential tariffs remain unknown.
President Donald Trump’s (R) plan to place tariffs on foreign pharmaceuticals could destabilize 340B drugs’ prices unless drugmakers absorb the [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

State Contract Pharmacy Lawsuit Roundup: 5th Circuit Appeals in Louisiana, 4th Circuit Appeal in West Virginia 

Key briefs were filed recently in state contract pharmacy litigation in West Virginia and Louisiana.
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

SK Life Science Announces 340B Refunds for Epilepsy Treatment

New Jersey-based SK Life Science announced refunds for 340B covered entities that purchased certain formulations of anti-seizure drug XCOPRI.
SK Life Science recently issued a refund notice for an epilepsy drug following a 340B price ceiling recalculation. The New [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

J&J Adds Unbranded Version of Stelara to 340B Contract Pharmacy Restrictions

J&J has added the unbranded version of its top-selling psoriatic arthritis treatment Stelara to its 340B contract pharmacy restrictions.
Johnson & Johnson (J&J) added Ustekinumab, the unbranded version of psoriatic arthritis treatment Stelara, to its 340B contract pharmacy restrictions [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Closed Pennsylvania Hospital Revives 340B Antitrust Lawsuit Against CVS’ TPA Wellpartner

Brandywine Hospital amended its legal filing in a class action case against a CVS contract pharmacy policy.
A shuttered Philadelphia-area hospital recently amended its legal filing in a class action case against CVS Health’s (CVS) contract pharmacy [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

State Contract Pharmacy Lawsuit Roundup: 4th Circuit Appeals in West Virginia, Maryland

Key briefs were filed recently in state contract pharmacy litigation in West Virginia and Maryland.
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Virginia Governor Signs Bill Protecting 340B Hospitals from PBM Discrimination

Virginia Gov. Glenn Youngkin (R) signed a bill on March 24 to expand the state's existing 340B PBM anti-discrimination law to also apply to hospitals.
Virginia Gov. Glenn Youngkin (R) signed a bill this week that will expand the state’s existing 340B pharmacy benefit manager [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Merck is First to Exempt South Dakota from 340B Contract Pharmacy Restrictions but Reinstates in Kansas, Novartis Exempts Missouri 

Merck announced it will exempt South Dakota from its contract pharmacy restrictions and reinstate them in Kansas. Novartis will exempt Missouri from its contract pharmacy restrictions.
Drugmakers Merck and Novartis recently updated their 340B contract pharmacy restrictions, modifying what states are exempt from such policies following [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Trump’s HHS Continues to Oppose Unilateral Drugmaker 340B Rebates in Kalderos Lawsuit

HHS filed a motion for summary judgement against Kalderos, the drug industry vendor behind Eli Lilly’s rebate proposal.
The Trump administration this week continued to oppose drug industry attempts to unilaterally convert 340B discounts to a rebate model, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live